Skip to Content

Carisoprodol Disease Interactions

There are 3 disease interactions with carisoprodol:

Major

Carisoprodol (Includes carisoprodol) ↔ porphyria

Major Potential Hazard, High plausibility. Applies to: Porphyria

The use of carisoprodol is contraindicated in patients with acute intermittent porphyria. Carisoprodol is partially metabolized to the pharmacologically active meprobamate, which has been reported to precipitate acute attacks of porphyria in susceptible patients.

References

  1. Hazen PG "Pseudoporphyria in a patient receiving carisoprodol/aspirin therapy." J Am Acad Dermatol 31 (1994): 500
  2. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  3. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.
Moderate

Carisoprodol (Includes carisoprodol) ↔ drug dependence

Moderate Potential Hazard, Moderate plausibility. Applies to: Alcoholism, Drug Abuse/Dependence

Carisoprodol is partially metabolized to meprobamate, a pharmacologically active agent with known addictive potential. According to the manufacturer, abrupt cessation of carisoprodol 100 mg/kg/day (approximately 5 times the recommended daily adult dosage) was associated with mild withdrawal symptoms such as abdominal cramps, insomnia, headache, nausea and chills in some study subjects. In clinical use, psychological dependence and abuse have been rare. Nevertheless, therapy with carisoprodol should be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. Morse RM, Chua L "Carisoprodol dependence: a case report." Am J Drug Alcohol Abuse 5 (1978): 527-30
  2. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.
  3. Elder NC "Abuse of skeletal muscle relaxants." Am Fam Physician 44 (1991): 1223-6
  4. Luehr JG, Meyerle KA, Larson EW "Mail-order (veterinary) drug dependence." JAMA 263 (1990): 657
View all 4 references
Moderate

Carisoprodol (Includes carisoprodol) ↔ renal/liver disease

Moderate Potential Hazard, High plausibility. Applies to: Liver Disease, Renal Dysfunction

Carisoprodol is primarily converted in the liver to several metabolites, one of which (meprobamate) is pharmacologically active. The metabolites and a small amount of the parent drug are excreted in the urine. Patients with impaired renal and/or hepatic function may be at greater risk for adverse effects due to drug and metabolite accumulation. Therapy with carisoprodol should be administered cautiously in such patients.

References

  1. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.

Carisoprodol drug interactions

There are 329 drug interactions with carisoprodol

Carisoprodol alcohol/food interactions

There is 1 alcohol/food interaction with carisoprodol

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.